What will imux do today, bullish spike again closing

Here is the analysis for Immunic (IMUX) stock:

1. **Recent Performance**: Immunic (IMUX) experienced a pre-market percentage change of 3.35% on September 19, 2024, and a post-market percentage change of 0% on September 18, 2024.

2. **Analyst Ratings and Price Targets**:
- The stock has received a consensus rating of "Buy" from six ratings firms, with five research analysts rating it as "Buy" and one as "Strong-Buy".
- Analysts at EF Hutton Acquisition Co. I upgraded IMUX to a "Strong-Buy" rating.
- Leerink Partners reissued an "Outperform" rating and set a price target of $5.00.
- B. Riley initiated coverage with a "Buy" rating and a price target of $6.00.
- Piper Sandler maintained an "Overweight" rating and set a price target of $28.00.
3. **Financial Performance**: IMUX reported a Q3 2024 earnings per share estimate of ($0.22) from Leerink Partnrs. The consensus estimate for the company's current full-year earnings is ($0.94) per share.
4. **Market Sentiment**:
- The stock has been given a "Buy" consensus by analysts, with an average target price of $11.20.
- There has been a recent surge in the stock's price due to positive interim data from a Phase 2 trial for a treatment for progressive multiple sclerosis.

5. **Technical Indicators**: The stock has a 50-day simple moving average of $1.38 and a 200-day simple moving average of $1.31. It traded up $0.01 on Monday, reaching $1.61.
6. **Institutional Activity**: There have been recent additions and reductions in institutional stakes, with BVF Inc. IL, Janus Henderson Group PLC, and Vanguard Group Inc. making changes to their holdings.

Given the positive analyst ratings, the potential of the company's drug candidates, and the recent surge in the stock's price due to positive trial data, there is a bullish sentiment surrounding Immunic (IMUX). However, the company's financial performance shows a loss, and the stock's technical indicators show a slight increase in price, but it is still within a relatively narrow range. Institutional activity suggests some confidence from large investors, but also indicates that there are mixed views on the company's future performance. Therefore, while there is potential for a bullish spike in the stock's price, it is important to consider the overall mixed picture before making any investment decisions.